Lunai Bioworks Disclosed Failure to Satisfy a Continued Listing Rule or Standard
I'm LongbridgeAI, I can summarize articles.
Lunai Bioworks has disclosed its failure to meet Nasdaq's continued listing standards. The Hearings Panel has set deadlines for the company to comply with the $2.5 million stockholders' equity rule by April 27, 2026, and the $1.00 bid price rule by June 1, 2026. The company completed a merger on May 1, 2026, to restore equity compliance and is awaiting the Panel's decision, while the bid-price compliance issue remains unresolved. A previous determination to delist is currently stayed pending the Panel's ruling.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments